LINX Reflux Management System
Commercial- Indications
- Gastroesophageal Reflux Disease (GERD)
Company intelligence / Profile preview
The company’s LINX Reflux Management System received FDA approval in 2012 for the treatment of GERD and has been marketed to physicians across the US and Europe. Clinical trials confirmed its safety and efficacy for acid reflux. The FENIX Continence Restoration System was developed for fecal incontinence[1][3].
Torax built a network of gastroenterologists trained to implant its devices before being acquired by Ethicon, a Johnson & Johnson company[2][4].
No new clinical programs have been reported since acquisition.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Torax Medical.